MacroGenics to Present at the Roth Capital Partners 27th Annual Growth Stock Conference
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage
biopharmaceutical company focused on discovering and developing
innovative monoclonal antibody-based therapeutics for the treatment
of cancer, as well as autoimmune disorders and infectious diseases,
today announced that Scott Koenig, M.D., Ph.D., President and CEO
will present at the 27th Annual Roth Conference in Dana
Point, CA. The presentation will take place on Tuesday, March 10,
2015 at 11:00 a.m. Pacific Time.
A live webcast of MacroGenics' presentation may be accessed
under "Events & Presentations" in the Investor Relations
section of the Company's website at
http://ir.macrogenics.com/events.cfm. MacroGenics will maintain
an archived replay of the webcast on its website for 30 days after
the conference.
About MacroGenics, Inc.
MacroGenics is a clinical-stage biopharmaceutical company
focused on discovering and developing innovative monoclonal
antibody-based therapeutics for the treatment of cancer, as well as
autoimmune disorders and infectious diseases. The Company generates
its pipeline of product candidates from its proprietary suite of
next-generation antibody-based technology platforms. The
combination of MacroGenics' technology platforms and protein
engineering expertise has allowed the Company to generate promising
product candidates and enter into several strategic collaborations
with global pharmaceutical and biotechnology companies. For more
information, please see the Company's website at www.macrogenics.com. MacroGenics
is a registered trademark of MacroGenics, Inc.
Cautionary Note on Forward-Looking
Statements
Any statements in this press release about future expectations,
plans and prospects for the Company, including statements about the
Company's strategy, future operations, clinical development of the
Company's therapeutic candidates, milestone or opt-in payments from
the Company's collaborators, the Company's future expectations and
plans and prospects and other statements containing the words
"anticipate," "believe," "estimate," "expect," "intend," "may,"
"plan," "predict," "project," "target," "potential," "will,"
"would," "could," "should," "continue," and similar expressions,
constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors, including: the
uncertainties inherent in the initiation and enrollment of future
clinical trials, expectations of expanding ongoing clinical trials,
availability and timing of data from ongoing clinical trials,
expectations for regulatory approvals, other matters that could
affect the availability or commercial potential of the Company's
product candidates and other risk factors described in the
Company's filings with the Securities and Exchange Commission,
including those discussed in the "Risk Factors" section of the
Company's Annual Report on Form 10-K filed with the Securities and
Exchange Commission on March 20, 2014 and the subsequent Quarterly
Reports on Form 10-Q. In addition, the forward-looking statements
included in this press release represent the Company's views as of
the date hereof. The Company anticipates that subsequent events and
developments will cause the Company's views to change. However,
while the Company may elect to update these forward-looking
statements at some point in the future, the Company specifically
disclaims any obligation to do so. These forward-looking statements
should not be relied upon as representing the Company's views as of
any date subsequent to the date hereof.
CONTACT: Jim Karrels, Senior Vice President, CFO
MacroGenics, Inc.
1-301-251-5172, info@macrogenics.com
Karen Sharma, Vice President
MacDougall Biomedical Communications
1-781-235-3060, ksharma@macbiocom.com
Source:
MacroGenics, Inc.
News Provided by Acquire Media
